{"entity":{"id":"nct06956170","kind":"trial","name":"All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myelo","aka":[],"tldr":"A phase 3 trial of Belantamab mafodotin, Pomalidomide, Dexamethasone in multiple myeloma, run by GlaxoSmithKline, active and no longer recruiting.","summary":"All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma is a phase 3 interventional study registered as NCT06956170 by GlaxoSmithKline, with 21 participants enrolled, started 2022-02-10 and due to reach its primary completion in 2024-05-27. Interventions recorded: Belantamab mafodotin, Pomalidomide, Dexamethasone, Bortezomib. Conditions listed: Multiple Myeloma. Results were posted on ClinicalTrials.gov in 2025; the figures recorded here are the registry's, not a publication's.","status":"active","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT06956170","url":"https://clinicaltrials.gov/study/NCT06956170"}],"tags":["ctgov-ingest"],"related":[],"cancers":["multiple-myeloma","myeloma-relapsed-refractory"],"sections":[],"technologies":["adc","antiemetic-therapy","kinase-inhibitors","protac-degrader"],"targets":[],"drugs":["belantamab-mafodotin","pomalidomide","dexamethasone","bortezomib"],"companies":["gsk"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06956170","phase":"3","setting":"A Phase III, Multicenter, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Pomalidomide and Dexamethasone (B-Pd) Versus Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Participants With Relapsed/Refractory Multiple Myeloma (DREAMM 8)","sponsor":"GlaxoSmithKline","started":"2022-02-10","startedType":"actual","yearReported":2025,"enrolled":21,"enrolledBasis":"registry","outcomes":[{"endpoint":"Progression-Free Survival (PFS)","primary":true,"unit":"months","arms":[{"name":"Belantamab Mafodotin+Pomalidomide+Dexamethasone","n":10,"note":"The median and upper limit of 95% Confidence Interval were not estimable due to an insufficient number of participants with events within the length of follow-…; Figures from the ClinicalTrials.gov results section (first posted 2025-06-11), not from a publication"},{"name":"Bortezomib + Pomalidomide + Dexamethasone","n":11,"value":14.8,"note":"95% CI 1.9 to NA"}],"hr":0.53,"ci":[0.1,2.78],"source":"https://clinicaltrials.gov/study/NCT06956170?tab=results"}]},"route":"/trials/nct06956170/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"},{"id":"myeloma-relapsed-refractory","kind":"cancer","name":"Relapsed or refractory multiple myeloma","route":"/cancers/myeloma-relapsed-refractory/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"antiemetic-therapy","kind":"technology","name":"Antiemetics for chemotherapy-induced nausea and vomiting","route":"/technologies/antiemetic-therapy/"},{"id":"protac-degrader","kind":"technology","name":"PROTACs & molecular glues (targeted protein degradation)","route":"/technologies/protac-degrader/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"belantamab-mafodotin","kind":"drug","name":"Belantamab mafodotin","route":"/drugs/belantamab-mafodotin/"},{"id":"bortezomib","kind":"drug","name":"Bortezomib","route":"/drugs/bortezomib/"},{"id":"dexamethasone","kind":"drug","name":"Dexamethasone","route":"/drugs/dexamethasone/"},{"id":"pomalidomide","kind":"drug","name":"Pomalidomide","route":"/drugs/pomalidomide/"}],"company":[{"id":"gsk","kind":"company","name":"GSK","route":"/companies/gsk/"}]}}